Interferon: Ten stories in one. A short review of some of the highlights in the history of an almost quinquagenarian

Acta Microbiologica et Immunologica Hungarica

Volumn 52, Issue 3-4, 2005, Pages 273-289

  De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

3 deazaneplanocin A; Interferon ; Interferon ; Poly(I) poly(C); Polyacrylic acid

Indexed keywords

EBOLA VIRUS; ENTEROVIRUS; FLAVIVIRUS; HEPATITIS C VIRUS;

EID: 29144503105     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.52.2005.3-4.2     Document Type: Short Survey

References (42)

1. Isaacs, A., Lindenmann, J.: Virus interference. I. The interferon. Proc Royal Soc London 147, 258-267 (1957).
2. De Somer, P., De Clercq, E., Billiau, A., Schonne, E., Claesen, M.: Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro. J Virol 2, 878-885 (1968).
3. De Somer, P., De Clercq, E., Billiau, A., Schonne, E., Claesen, M.: Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol 2, 886-893 (1968).
4. Merigan, T. C.: Induction of circulating interferon by synthetic anionic polymers of known composition. Nature 214, 416-417 (1967).
5. Merigan, T. C., Regelson, W.: Interferon induction in man by a synthetic polyanion of defined composition. N Engl J Med 277, 1283-1287 (1967).
6. De Clercq, E., De Somer, P.: Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus. Life Sci 7, 925-933 (1968).
7. De Clercq, E., De Somer, P.: Effect of interferon, polyacrylic: acid, and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl Microbiol 16,1314-1319 (1968).
8. Lampson, G. P., Tytell, A. A., Field, A. K., Nemes, M. M., Hilleman, M. R.: Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funicolosum. Proc Natl Acad Sci USA 58, 782-789 (1967).
9. Field, A. K., Tytell, A. A., Lampson, G. P., Hilleman, M. R.: Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci USA 58, 1004-4010 (1967).
10. Tytell, A. A., Lampson, G. P., Field, A. K., Hilleman, M. R.: Inducers of interferon and host resistance. III. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA). Proc Natl Acad Sci USA 58, 1719-1722 (1967).
11. Field, A. K., Lampson, G. P., Tytell, A. A., Hilleman, M. R.: Inducers of interferon and host resistance. IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. Proc Natl Acad Sci USA 58, 2102-2108 (1967).
12. Field, A. K., Tytell, A. A., Lampson, G. P., Hilleman, M. R.: Inducers of interferon and host resistance. V. In vitro studies. Proc Natl Acad Sci USA 61, 340-346 (1968).
13. De Clercq, E.: Synthetic interferon inducers. Topics in Current Chemistry 52, 173-208 (1974).
14. Nemes, M. M., Tytell, A. A., Lampson, G. P., Field, A. K., Hilleman, M. R.: Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Proc Soc Exp Biol Med 132, 776-783 (1969).
15. Nemes, M. M., Tytell, A. A., Lampson, G. P., Field, A. K., Hilleman, M. R.: Inducers of interferon and host resistance. VII. Antiviral efficacy of double-stranded RNA of natural origin. Proc Soc Exp Biol Med 132, 784-789 (1969).
16. Field, A. K., Young, C. W., Krakoff, I. H., Tytell, A. A., Lampson, G. P., Nemes, M. M., Hilleman, M. R.: Induction of interferon in human subjects by poly I:C. Proc Soc Exp Biol Med 136, 1180-1186 (1971).
17. De Clercq, E., Nuwer, M. R., Merigan, T. C.: The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. J Clin Invest 49, 1565-1577 (1970).
18. De Clercq, E., De Somer, P.: Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid. Science 173, 260-262 (1971).
19. Carter, W. A., De Clercq, E.: Viral infection and host defense (many aspects of viral infection and recovery can be explained by the modulatory role of double-stranded RNA). Science 186, 1172-1178 (1974).
20. De Clercq, E., Edy, V. G., Torrence, P. F., Waters, J. A., Witkop, B.: Antiviral activity of poly(7-deazainosinic acid)-derived complexes in vitro and in vivo. Mol Pharmacol 12, 1045-1051 (1976).
21. De Clercq, E.: Interferon: a molecule for all seasons. In: Olson, L. C. (ed.), Virus Infections. Modern Concepts and Status. Marcel Dekker, Inc., New York, 1982, pp. 87-138.
22. n. complex for induction of human interferon. J Mol Biol 70, 567-587(1972).
23. Carter, W. A., Strayer, D. R., Brodsky, I., Lewin, M., Pellegrino, M. G., Einck, L., Henriques, H. F., Simon, G. L., Parenti, D. M., Scheib, R. G.: Clinical, immunological, and virological effects of ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1, 1286-1292 (1987).
24. Derynck, R., Content, J., De Clercq, E., Volckaert, G., Tavernier, J., Devos, R., Fiers, W.: Isolation and structure of a human fibroblast interferon gene. Nature 285, 542-547 (1980).
25. Derynck, R., Remaut, E., Saman, E., Stanssens, P., De Clercq, E., Content, J., Fiers, W.: Expression of human fibroblast interferon gene in Escherichia coli. Nature 287, 193-197 (1980).
26. Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E., Fiers, W.: Secretory proteins induced in human fibroblasts under conditions used for the production of interferon-β. Proc Natl Acad Sci USA 79, 2768-2772 (1982).
27. Weissenbach, J., Chernajovsky, Y., Zeevi, M., Shulman, L., Soreq, H., Nir, U., Wallach, D., Perricaudet, M., Tiollais, P., Revel, M.: Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 77, 7152-7156 (1980).
28. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
29. Revel, M.: Interferon-β in the treatment of relapsing-remitting multiple sclerosis. Pharmacol Ther 100, 49-62 (2003).
30. Hadziyannis, S. J., Sette Jr., H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, R., Bodenheimer H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P. J., Lin, A., Ackrill, A. M.: Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 140, 346-355 (2004).
31. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr, H. W.: Treatment of SARS with human interferons. Lancet 362, 293-294 (2003).
32. Ströher, U., DiCaro, A., Li, Y., Strong, J. E., Aoki, F., Plummer, F., Jones, S. M., Feldmann, H.: Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 189, 1164-1167 (2004).
33. Hensley, L. E., Fritz, E. A., Jahrling, P. B., Karp, C. L., Huggins, J. W., Geisbert, T. W.: In-terferon-β 1a and SARS coronavirus replication. Emerg Infect Dis 10, 317-319 (2004).
34. Sainz, B., Jr., Mossel, E. C., Peters, C. J., Garry, R. F.: Interferon-β and interferon-γy synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329, 11-17 (2004).
35. Haagmans, B. L., Kuiken, T., Martina, B. E., Fouchier, R. A. M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan, K.-H., Tashiro, M., Osterhaus, A. D. M. E.: Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus (SCV) infection in macaques. Nature Med 10, 290-293 (2004).
36. Leyssen, P., Drosten, C., Paning, M., Charlier, N., Paeshuyse, J., De Clercq, E., Neyts, J.: Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 47, 777-782 (2003).
37. 12U)] markedly protects mice against Coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 48, 267-274 (2004).
38. Bray, M.: Defense against filoviruses used as biological weapons. Antiviral Res 57, 53-60 (2003).
39. Jährling, P. B., Geisbert T. W., Geisbert, J. B., Swearengen, J. R., Bray, M., Jaax, N. K., Huggins, J. W., LeDuc, J. W., Peters, C. J.: Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 179, Suppl. 1, S224-S234 (1999).
40. Bray, M., Driscoll, J., Huggins, J. W.: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 45, 135-147 (2000).
41. Bray, M., Raymond, J. L., Geisbert, T., Baker, R. O.: 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice. Antiviral Res 55, 151-159 (2002).
42. De Clercq, E.: Antivirals and antiviral strategies. Nature Rev Microbiol 2,704-720 (2004).